CMPX
Compass Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$318.76M
P/E Ratio
—
EPS
$-0.42
Beta
1.30
52W High
$6.88
52W Low
$1.61
50-Day MA
$5.20
200-Day MA
$4.61
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Compass Therapeutics Inc.
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-72.56M |
| Operating Margin | 0.00% |
| Return on Equity | -41.30% |
| Return on Assets | -25.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.10 |
| Price-to-Book | 1.63 |
| Price-to-Sales (TTM) | 269.28 |
| EV/Revenue | 109.28 |
| EV/EBITDA | -8.92 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $180.09M |
| Float | $118.87M |
| % Insiders | 12.46% |
| % Institutions | 88.24% |
Historical Volatility
HV 10-Day
105.88%
HV 20-Day
79.18%
HV 30-Day
70.60%
HV 60-Day
57.54%
HV Rank
70.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.25 target)
3
Strong Buy13
BuyData last updated: 5/1/2026